<DOC>
	<DOCNO>NCT00522392</DOCNO>
	<brief_summary>This randomized phase III trial compare bortezomib , dexamethasone , lenalidomide bortezomib dexamethasone see well work treat patient multiple myeloma previously treat dexamethasone . Bortezomib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , dexamethasone , work different way stop growth cancer cell , either kill cell stop dividing . Lenalidomide may stimulate immune system different way stop cancer cell grow . It yet know whether give bortezomib dexamethasone effective without lenalidomide treat multiple myeloma .</brief_summary>
	<brief_title>Bortezomib Dexamethasone With Without Lenalidomide Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare progression-free survival ( PFS ) two consolidation regimen : bortezomib , lenalidomide , dexamethasone ( VRD ) versus bortezomib dexamethasone ( VD ) . SECONDARY OBJECTIVES : I . To determine incremental ability VRD versus VD attain complete response good partial response ( VGPR ) patient receive induction therapy dexamethasone base induction regimen . II . To compare overall survival , measure time study entry . III . Evaluate response rate PFS accord cytogenetic category ( gene expression fluorescence situ hybridization [ FISH ] ) . IV . To evaluate toxicity two regimen . V. To compare quality life ( QOL ) base Functional Assessment Cancer Therapy ( FACT ) -Neurotoxicity ( Ntx ) Trial Outcome Index ( TOI ) patient receive VD receive VRD registration 6 month post consolidation treatment . VI . To examine impact differential treatment response ( PFS ) , observe , QOL base FACT-Ntx TOI 12 month post consolidation treatment . VII . To obtain prospective data multiple myeloma specific QOL attribute . OUTLINE : Patients randomize 1 2 treatment arm . ARM A : Patients receive bortezomib 1.3 mg/m2 intravenously ( IV ) day 1 , 4 , 8 , 11 , lenalidomide orally ( PO ) daily ( QD ) 15 mg day 1-14 , dexamethasone 40 mg total dose per day PO QD day 1 , 8 , 15 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . ARM B : Patients receive bortezomib 1.3 mg/m2 IV day 1 , 4 , 8 , 11 dexamethasone 40 mg total dose per day PO QD day 1 , 8 , 15 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year , every 6 month 3 year , every 12 month 5 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Symptomatic multiple myeloma , symptomatic time initial diagnosis , may asymptomatic time registration base induction therapy For original diagnosis myeloma , patient must meet follow criterion one point disease course : bone marrow plasmacytosis ( &gt; 10 % plasma cell sheet plasma cell ) biopsy proven plasmacytoma , evidence endorgan damage due multiple myeloma include anemia , hypercalcemia , bone disease ( lytic bone lesion pathologic fracture ) renal dysfunction . Patients may prior exposure bortezomib Patients must receive minimum 1 cycle , maximum 6 cycle , dexamethasonebased regimen ; patient must experience progressive disease therapy The following induction regimen consider adequate enrollment : dexamethasone alone ; vincristine , doxorubicin dexamethasone ; thalidomide dexamethasone ; lenalidomide dexamethasone ; liposomal doxorubicin dexamethasone ; combination agent dexamethasone ; cyclophosphamide , lenalidomide dexamethasone Patients must receive minimum cumulative dose dexamethasone 160 mg ( sum induction treatment ) maximum dose specified Patients must offer refuse frontline stem cell transplant OR eligible frontline stem cell transplant . Bone marrow aspiration and/or biopsy must obtain = &lt; 28 day prior randomization All test must perform = &lt; 28 day prior randomization : Kappa free light chain mg/dL Lambda free light chain mg/dL Serum Mprotein serum protein electrophoresis ( SPEP ) Urine Mprotein light chain excretion urine protein electrophoresis ( UPEP ) Adequate laboratory level within 7 day prior randomization : hemoglobin &gt; 7 g/dL , platelet count &gt; 75,000 cells/mm^3 , absolute neutrophil count &gt; 1000 cells/mm^3 , creatinine &lt; 2.5 mg/dL , creatinine clearance ( measure calculate ) &gt; = 60 mL/min , direct bilirubin = &lt; 1.5 mg/dL , serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) = &lt; 2.5 time upper limit normal Patients may receive bisphosphonates erythropoietin growth factor ( erythropoietic agent ) multiple myeloma Prior palliative and/or localize radiation therapy permit , provide least 14 day pass date last radiation therapy date randomization Patients must willing able take prophylaxis either aspirin 325 mg/day alternative prophylaxis either low molecular weight heparin coumadin ( patient prior deep vein thrombosis [ DVT ] eligible provide remain anticoagulation regimen prescribe treatment DVT throughout protocol therapy ) Patients must competent understand study explain consent form Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Sexually active male must willing use condom ( even undergone prior vasectomy ) intercourse woman , take lenalidomide , 4 week stop treatment Patients history prior malignancy eligible provide active malignancy low expectation recurrence within 6 month Age &gt; =18 year More 8 week last day last cycle induction treatment Active , uncontrolled seizure disorder ; seizure last 6 month Uncontrolled intercurrent illness would limit compliance study include uncontrolled hypertension , symptomatic congestive heart failure , unstable angina , uncontrolled cardiac arrhythmia , uncontrolled psychiatric illness social situation , prior history Stevens Johnson syndrome Grade 2 high peripheral neuropathy Common Terminology Criteria Adverse Events ( CTCAE ) version 3.0 Active , uncontrolled infection Smoldering myeloma monoclonal gammopathy undetermined significance Pregnant nursing woman eligible . Women childbearing potential unwilling use dual method contraception men unwilling use condom eligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Consolidation therapy</keyword>
	<keyword>First-line therapy</keyword>
	<keyword>Proteasome inhibitor</keyword>
	<keyword>Thalidomide analogue</keyword>
	<keyword>Quality life</keyword>
</DOC>